We are live on ! Find out more
TCON

TRACON Pharmaceuticals, Inc. Common Stock

Delisted

TCON was delisted on the 27th of June, 2024.

1 hedge funds and large institutions have $80 invested in TRACON Pharmaceuticals, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% less funds holding

Funds holding: 291 (-28)

100% less capital invested

Capital invested by funds: $1.39M → $80 (-$1.39M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 28

Holders
1
Holders Change
-28
Holders Change %
-96.55%
% of All Funds
0.01%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
28
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
-$3.26K -379 Closed
TC
27
Truvestments Capital
Florida
-$137 -16 Closed
Wells Fargo
28
Wells Fargo
California
-$89 -10 Closed

TCON Hedge Fund Activity: Q2 2024 in Review

1 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2024, worth a combined $80 — down 100% from $1.39M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of TCON and 0 opened new positions — a net loss of 28 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was LPL Financial, exiting entirely with an estimated $194K sold.

  • 1 institutional investor held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2024, down from 29 in Q1 2024.
  • Funds reported $80 of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2024 and 28 closed out, a net change of -28 holders.
  • The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2024 was LPL Financial, an estimated $194K sold.

Based on aggregated 13F filings for Q2 2024.